N-(2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)ethyl)thiazolidine-4-carboxamide | 1370343-66-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-(2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)ethyl)thiazolidine-4-carboxamide
• 英文别名: N-[2-(2,5-dioxopyrrol-1-yl)ethyl]-1,3-thiazolidine-4-carboxamide
• CAS: 1370343-66-0
• 化学式: C₁₀H₁₃N₃O₃S
• 分子量: 255.298
• InChiKey: JZIKTCHYMJPYKS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  104
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  N-(2-氨基乙基)马来酰亚胺 在 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 、 三氟乙酸 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 3.67h， 生成 N-(2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)ethyl)thiazolidine-4-carboxamide
  参考文献：
  名称：

  Site-Specific Traceless Coupling of Potent Cytotoxic Drugs to Recombinant Antibodies for Pharmacodelivery

  摘要：

  Aldehyde drugs are gaining increasing research interest, considering that aldehyde dehydrogenases overexpression is characteristic of cancer stem cells. Here, we describe the traceless site-specific coupling of a novel potent drug, containing an aldehyde moiety, to recombinant antibodies, which were engineered to display a cysteine residue at their N-terminus, or a 1,2-aminothiol at their C-terminus. The resulting chemically defined antibody-drug conjugates represent the first example in which a thiazolidine linkage is used for the targeted delivery and release of cytotoxic agents.

  DOI：

  10.1021/ja211589m

文献信息

• PROTEIN-DRUG CONJUGATES
  申请人：Philogen S.p.A.

  公开号：EP3842074A1

  公开（公告）日：2021-06-30

  In one aspect, there is provided a protein-drug conjugate compound comprising a protein covalently attached by a linker to one or more drug moieties, wherein the linker has a half-life of from 1 hour to 50 hours in phosphate buffered saline at 37 °C. A carbonyl derivative of LU103793 is also described that can be used in a protein-drug conjugate compound comprising an antibody covalently attached by a linker to the drug moiety comprising, consisting or consisting essentially of the carbonyl derivative.

  在一个方面，提供了一种蛋白质-药物共轭化合物，该化合物由通过连接体与一个或多个药物分子共价连接的蛋白质组成，其中连接体在 37 °C 磷酸盐缓冲盐水中的半衰期为 1 小时至 50 小时。还描述了一种 LU103793 的羰基衍生物，该衍生物可用于蛋白质-药物共轭化合物中，该化合物包括通过连接体与药物分子共价连接的抗体，药物分子包括或主要包括羰基衍生物。